{"filing":{"accession_number":"0001104659-26-094862","cik":"0001867066","ticker":"DERM","company_name":"Journey Medical Corp","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2622742d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm"},"events":[{"id":27162,"run_id":24740,"accession_number":"0001104659-26-094862","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Journey Medical issued a press release on August 12, 2026, announcing financial results for the three months ended June 30, 2026 (Q2 2026). The disclosure includes total revenues of $18.5 million (23% growth year-over-year), Emrosi® revenues of $8.1 million, gross margin of 67%, narrowed net loss of $0.3 million, and cash position of $25.6 million. This is a standard quarterly earnings release with consolidated financial statements and operational metrics, clearly falling under Item 2.02 Results of Operations and Financial Condition.","company_name":"Journey Medical Corp","ticker":"DERM","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28573,"accession_number":"0001104659-26-094862","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Journey Medical issued a press release on August 12, 2026, announcing financial results for the three months ended June 30, 2026 (Q2 2026). The disclosure includes total revenues of $18.5 million (23% growth year-over-year), Emrosi® revenues of $8.1 million, gross margin of 67%, narrowed net loss of $0.3 million, and cash position of $25.6 million. This is a standard quarterly earnings release with consolidated financial statements and operational metrics, clearly falling under Item 2.02 Results of Operations and Financial Condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:08:59.579400+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28573,"accession_number":"0001104659-26-094862","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Journey Medical issued a press release on August 12, 2026, announcing financial results for the three months ended June 30, 2026 (Q2 2026). The disclosure includes total revenues of $18.5 million (23% growth year-over-year), Emrosi® revenues of $8.1 million, gross margin of 67%, narrowed net loss of $0.3 million, and cash position of $25.6 million. This is a standard quarterly earnings release with consolidated financial statements and operational metrics, clearly falling under Item 2.02 Results of Operations and Financial Condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:08:59.579400+00:00","company_name":"Journey Medical Corp","ticker":"DERM","filing_date":"2026-08-12"}]}